Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Craters on the melanoma surface serve as hubs for CD8+ T cells [ATAC-Seq]

ABSTRACT: Immune cell interactions with tumor cells are critical for cancer therapeutic response, but it is unclear whether T cells take a direct or random path into a tumor. We performed 3D, long-term imaging of zebrafish melanomas and found that CD8+ T cells localize to craters on the tumor surface. Craters are the primary site of CD8 T cells accumulation and activation following CpG oligonucleotide injection, TLR agonists that elicit an immune response, or systemic TGF-β inhibition. Human melanomas exhibit craters at the tumor surface and in perivascular spaces where they harbor dysfunctional, proliferative CD8+ T cells. In both zebrafish and human tumors, crater size and number positively correlate with CD8+ T cell infiltration. These results identify craters as hubs that provide a direct path for CD8+ T cells into tumors.

ORGANISM(S): Danio rerio

PROVIDER: GSE213263 | GEO | 2025/09/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Craters on the melanoma surface serve as hubs for CD8+ T cells [RNA-Seq]

Project description:Immune cell interactions with tumor cells are critical for cancer therapeutic response, but it is unclear whether T cells take a direct or random path into a tumor. We performed 3D, long-term imaging of zebrafish melanomas and found that CD8+ T cells localize to craters on the tumor surface. Craters are the primary site of CD8 T cells accumulation and activation following CpG oligonucleotide injection, TLR agonists that elicit an immune response, or systemic TGF-β inhibition. Human melanomas exhibit craters at the tumor surface and in perivascular spaces where they harbor dysfunctional, proliferative CD8+ T cells. In both zebrafish and human tumors, crater size and number positively correlate with CD8+ T cell infiltration. These results identify craters as hubs that provide a direct path for CD8+ T cells into tumors.

2025-09-12 | GSE213285 | GEO

CRATER tumor niches facilitate CD8+ T cell engagement and correspond with immunotherapy success [Spatial transcriptomics]

Project description:T cell-mediated tumor killing underlies immunotherapy success. Here, we used long-term in vivo imaging and high-resolution spatial transcriptomics of zebrafish endogenous melanoma, as well as multiplex imaging of human melanoma, to identify domains facilitating the immune response during immunotherapy. We identified cancer regions of antigen presentation and T cell engagement and retention (CRATERs) as pockets at the stroma-melanocyte boundaries of zebrafish and human melanoma. CRATERs are rich in antigen-recognition molecules, harboring the highest density of CD8+ T cells in tumors. In zebrafish, CD8+ T cells formed prolonged interactions with melanoma cells within CRATERs, characteristic of antigen recognition. Following immunostimulatory treatment, CRATERs expanded, becoming the major sites of activated CD8+ T cell accumulation and tumor killing. In humans, elevation in CRATER density in biopsies following immune checkpoint blockade (ICB) therapy correlated with a clinical response to therapy. CRATERs are structures that show active tumor killing and may be useful as a diagnostic indicator for immunotherapy success.

2025-12-29 | GSE312604 | GEO

IL-12 induces myeloid cells in situ to cross-present antigen

Project description:Myeloid-derived cells comprising the tumor stroma represent a heterogeneous population of cells critical to the structure, function and growth of established cancers. We have recently found that engineering tumor-specific CD8+ T cells to secrete IL-12 (IL-12TD) can lead to striking improvements in T-cell activity against established melanomas in murine models. Surprisingly, IL-12-dependent enhancement of CD8+ T-cell anti-tumor function did not occur through direct ligation of receptors on lymphocytes or NK cells. Instead, IL-12 sensitized host bone marrow-derived tumor-stromal cells, partly through interferon-gamma, to indirectly enhance the effects of adoptively-transferred T cells. Direct presentation of antigen by tumor was not necessary, but MHC class I expression on endogenous cells was essential for IL-12 mediated anti-tumor enhancements. Upon successful treatment with IL-12TD cells, we observed the selective elimination of tumor-infiltrating CD11b+ F4/80+ macrophages, CD11b+/ClassII+/CD11c+ dendritic cells and CD11b+/Ly6C+/Ly6G- but not CD11b+/Ly6C+/Ly6G+ myeloid-derived suppressor cells within regressing lesions. These results are consistent with a model whereby IL-12 triggers the maturation of myeloid-derived cells into competent antigen cross-presenting cells. Licensed recognition of these antigens by effector T cells may in turn trigger the collapse of the tumor stroma and aid in the regression of large vascularized lesions. Samples were collected at 3 days and 7 days from tumors treated in-vivo with no treatment, Mock pmel-1 CD8+ cell treatment, or IL-12 pmel-1 CD8+ cell treatment. There were 4 biological replicates of each sample type. There were a total of 24 samples.

2012-04-22 | E-GEOD-29164 | biostudies-arrayexpress

Craters on the melanoma surface serve as hubs for CD8+ T cells

Project description:Craters on the melanoma surface serve as hubs for CD8+ T cells

| PRJNA880332 | ENA

Nanoinducers-mediated Mitochondria-Selective Degradation Enhance T Cell Immunotherapy Against Multiple Cancers

Project description:<p>Cancer immunotherapy utilizing cytotoxic T lymphocytes (CTLs) has demonstrated significant promise in clinical applications, but cancer immunosuppressive mechanisms hamper further progress in T cell immunotherapy. Here we show a correlation between cancer cell mitochondria content and their resistance to immunotherapy. Observing that cancer cells with higher mitochondrial content show increased resistance to CD8+ T cells, we developed mitochondrial nanoinducers designed to selectively target and degrade mitochondria within autophagosomes. The direct degradation of mitochondria not only enhances the recognition and activation of CD8+ T cells but also increases the susceptibility of cancer cells to CD8+ T cell-mediated cytotoxicity. We demonstrated the feasibility and efficacy of this strategy in multiple in vitro and in vivo tumor therapeutic models. This nanoinducer, designed to manipulate cellular mitochondrial degradation, holds promise as a versatile tool for enhancing adoptive T-cell therapy, CAR T-cell therapy and tumor vaccine-based immunotherapy.</p>

2025-03-13 | MTBLS12284 | MetaboLights

CRaTER enrichment for on-target gene-editing enables generation of variant libraries in hiPSCs

Project description:Generation of transgenic cell lines is limited by inefficient gene editing requiring genotypic screening of hundreds to thousands of colonies to isolate correctly gene-edited cells. Here, we describe a novel method called CRISPRa On-Target Editing Retrieval (CRaTER) that enriches for cells with on-target knock-in of a promoterless cDNA-fluorescent reporter transgene by transiently overexpressing the targeted endogenous genetic locus and sorting for fluorescent cells. We use CRaTER to enrich for rare cells with heterozygous, biallelic-editing of the endogenous, transcriptionally-inactive MYH7 locus in human induced pluripotent stem cells (hiPSC), resulting in a 9-fold enrichment compared to antibiotics selection alone. We leveraged CRaTER to enrich for heterozygous knock-in of a library of single nucleotide variants (SNV) in MYH7, a gene encoding for sarcomeric MHC-β wherein autosomal dominant missense mutations cause cardiac and skeletal myopathies. CRaTER enabled 90% enrichment of heterozygous, biallelically-edited hiPSCs – a 38.6-fold enrichment compared to antibiotics selection alone – to generate 113 SNVs comprising 78 missense variants in MYH7. hiPSCs that have undergone CRaTER enrichment can differentiate to cardiomyocytes and exhibit expected localization and expression of MHC-β fusion proteins. Together, CRaTER substantially reduces the screening required for isolation of gene-edited cells, enabling the generation of transgenic cell lines at unprecedented scale.

2023-01-31 | GSE213520 | GEO

Expression analysis of melanoma harvested from GFP versus SETDB1 transgenic zebrafish (Danio rerio)

Project description:Investigation of expression differences between melanomas harvested from MiniCoopR-GFP versus MiniCoopR-SETDB1 transgenic zebrafish. An eight-chip study using total RNA prepared from four distinct melanomas from zebrafish injected with MiniCoopR-GFP (control) transposon and four distinct melanomas from zebrafish injected with MiniCoopR-SETDB1 transposon. Injected animals carried a p53 loss-of-function mutation, a mutation in nacre, and an mitf:BRAF-V600E transgene. Each chip measures the expression level of 32,292 genes.

2011-01-07 | E-GEOD-21505 | biostudies-arrayexpress

IL-12 induces myeloid cells in situ to cross-present antigen

2012-04-23 | GSE29164 | GEO

The novel protein circPETH-147aa regulates metabolic reprogramming in hepatocellular carcinoma cells to remodel immunosuppressive microenvironment

Project description:Metabolic reprogramming fuels cancer cell metastasis and remodels the immunosuppressive tumor microenvironment (TME). We report here that a circRNA, circPETH, packaged by extracellular vesicles (EVs) from tumor-associated macrophages (TAMs) to hepatocellular carcinoma (HCC) cells, facilitates glycolysis and metastasis of recipient HCC cells. Mechanistically, circPETH-147aa, encoded by circPETH in a m6A-driven manner, promotes PKM2-catalyzed ALDOA-S36 phosphorylation via MEG pocket. Furthermore, circPETH-147aa impairs anti-HCC immunity by elevating HuR-dependent SLC43A2 mRNA stability and driving methionine and leucine deficiency in cytotoxic CD8+ T cells. Importantly, by virtual and experimental screening, we found that the novel small-molecule Norathyriol was an effective inhibitor that targets the MEG pocket on circPETH-147aa surface. Norathyriol reverses circPETH-147aa-facilitated acquisition of metabolic and metastatic phenotypes by HCC cells, increases anti-PD1 efficacy and boosts cytotoxic CD8+ T-cell function. Our findings determine Norathyriol as a promising anti-HCC agent that contributes to the attenuation of advanced HCC resistance to immune checkpoint blocker (ICB) therapies.

2024-12-09 | MTBLS11254 | MetaboLights

Craters on the melanoma surface serve as hubs for CD8+ T cells [ATAC-Seq]

Project description:Craters on the melanoma surface serve as hubs for CD8+ T cells [ATAC-Seq]

| PRJNA880291 | ENA